Wall Street Loses Faith in Fortive’s Growth Trajectory

A wave of skepticism has swept through Wall Street regarding Fortive Corp.’s near-term prospects, as multiple prominent financial institutions dramatically downgraded their outlook for the industrial conglomerate. This collective shift in sentiment follows disappointing quarterly results and raises questions about the company’s strategic direction following its recent corporate separation.

Major Institutions Slash Targets

The reassessment began in earnest when Morgan Stanley downgraded Fortive from “Overweight” to “Equal Weight” on Tuesday. In a particularly stark adjustment, the firm slashed its price target from $90 to $50 per share. This move triggered similar actions across the sector: Barclays reduced its target from $58 to $54, Truist Securities adjusted from $60 to $55, and Wells Fargo cut its projection from $72 to $55.

The consensus among the eighteen firms covering Fortive now paints a cautious picture. Thirteen maintain “Hold” recommendations while only five advocate “Buy” positions. The average price target across all analysts stands at $65.57, signaling a fundamental recalibration of expectations for the company’s performance.

Quarterly Performance Disappoints

Fortive’s second-quarter financial results provided little comfort to concerned investors. The company reported adjusted earnings per share of $0.58, falling short of the $0.60 consensus estimate. More troubling was the 0.4% decline in continuing business revenue, which dropped to $1.02 billion. This stagnation marks a significant departure from the mid-single-digit growth rates that previously characterized the company’s performance.

Should investors sell immediately? Or is it worth buying Fortive?

Strategic Spin-Off Fails to Impress

The completion of the Ralliant separation on June 28 was intended to sharpen Fortive’s strategic focus and accelerate growth. Instead, the transaction appears to have exposed vulnerabilities within the remaining core business. A particular concern emerged regarding revenue concentration, with approximately 40% of sales dependent on U.S. government contracts and healthcare expenditures—sectors facing considerable uncertainty under current political conditions.

Technical indicators further compound the negative outlook. Fortive’s share price approaches its 52-week low of $46.34, with all major money flow indicators trending downward. The stock’s 20-day moving average has fallen below its 60-day counterpart, forming a classic bearish signal that technical analysts view with concern.

Diverging Outlooks Create Uncertainty

While management maintains an optimistic posture with EPS guidance between $2.50 and $2.60 for 2025, a significant gap exists between internal projections and analyst expectations of $4.05. Morgan Stanley cautioned investors that further earnings revisions could materialize if the company fails to achieve its projected 4% growth during the 2026-2027 period.

This disconnect between corporate guidance and market expectations leaves investors weighing whether to maintain positions during this period of uncertainty or seek opportunities elsewhere as Fortive navigates its post-spinoff challenges.